Literature DB >> 758133

Intracranial pressure in pigs with surgically induced acute liver failure.

M A Hanid, R L Mackenzie, R E Jenner, R A Chase, P J Mellon, P N Trewby, I Janota, M Davis, D B Silk, R Williams.   

Abstract

Cerebral edema has now been noted to occur frequently in patients dying of fulminant hepatic failure. In the present study, intracranial pressure was monitored in an animal model of acute liver failure. Acute liver failure was induced surgically by hepatic devascularization. Serial monitoring of the electroencephalogram revealed progressive slowing of the frequency with decreasing amplitude. Elevation of the blood ammonia was also observed from baseline values of 64 +/- 12 SE to 744 +/- 97 mumol/liter. Monitoring of the intracranial pressure with a subdural pressure transducer demonstrated a progressive and reproducible rise from 12.8 +/- 2.5 mm Hg immediately after the operation to a mean value of 51.6 +/- 11.8 mm Hg just before death 6--12 hr later. At autopsy, the brains of the test animals were found to be swollen with flattened cortical gyri. In the control animals, intracranial pressure rose slightly but returned toward normal levels (8.0 +/- 2.5 mm Hg) 8 hr after laparotomy and remained normal until their death. There was a statistically significant difference between intracranial pressure levels of the test animals and those of the controls (P less than 0.01). Intravenous methylprednisolone (2.0 g initially followed by 0.5 g every 2 hr) administered immediately before and after hepatic devascularization prevented rises in intracranial pressure but had no effect when given 4 hr after operation. The early and progressive increase in intracranial pressure was an unexpected finding, and an assessment of such a sequence in patients with fulminant hepatic failure is currently in progress.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 758133

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

Review 1.  Animal models of acute hepatic failure.

Authors:  T M Rahman; H J Hodgson
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  A Macaca mulatta model of fulminant hepatic failure.

Authors:  Ping Zhou; Jie Xia; Gang Guo; Zi-Xing Huang; Qiang Lu; Li Li; Hong-Xia Li; Yu-Jun Shi; Hong Bu
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

Review 3.  Animal models of fulminant hepatic failure.

Authors:  J Terblanche; R Hickman
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

4.  Mannitol treatment of cerebral edema in rats with galactosamine-induced severe hepatitis.

Authors:  W Zimmerli; C Grubinger; H Thölen; M Oberholzer; L Bianchi
Journal:  Experientia       Date:  1981-12-15

5.  Cerebral oedema and monitoring of intracranial pressure in fulminant hepatic failure.

Authors:  R Ede; A E Gimson; J Cannalese; R Williams
Journal:  Gastroenterol Jpn       Date:  1982-04

6.  Fulminant hepatic failure in childhood: an analysis of 31 cases.

Authors:  H T Psacharopoulos; A P Mowat; M Davies; B Portmann; D B Silk; R Williams
Journal:  Arch Dis Child       Date:  1980-04       Impact factor: 3.791

7.  Serum creatine kinase isoenzymes behavior in hepatic failure with encephalopathy.

Authors:  A Lemberg; M Schon; M C Macchi; L Galanternik; L Bengochea
Journal:  Dig Dis Sci       Date:  1981-10       Impact factor: 3.199

Review 8.  Reye's syndrome: a clinical review.

Authors:  J F Crocker; P C Bagnell
Journal:  Can Med Assoc J       Date:  1981-02-15       Impact factor: 8.262

9.  Electron microscopic study of the blood-brain barrier in rats with brain edema and encephalopathy due to acute hepatic failure.

Authors:  M Kato; J Sugihara; T Nakamura; Y Muto
Journal:  Gastroenterol Jpn       Date:  1989-04

10.  Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure.

Authors:  J Canalese; A E Gimson; C Davis; P J Mellon; M Davis; R Williams
Journal:  Gut       Date:  1982-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.